A Once-Monthly Weight-Loss Injection? A Chattanooga Physician on MariTide

I am Dr. Paul Miranda, a board-certified physician at Summit Metabolic Health. MariTide (maridebart cafraglutide) is investigational — it is in Phase 3 trials, not approved, and cannot be prescribed today. So this is education. But the question behind it — does dosing frequency matter as much as we think? — is one I answer for patients in Tennessee every week.

What MariTide Is, and Why “Monthly” Is Possible

MariTide works differently from the GLP-1 drugs you know. It is an antibody-based molecule that activates the GLP-1 receptor while blocking a second receptor called GIP. Curiously, tirzepatide produces weight loss by activating that same GIP receptor — opposite actions, both effective, because GIP signaling behaves differently in different tissues. The relevant point for patients is mechanical: MariTide’s antibody design gives it a long half-life of about three weeks, which is what makes once-monthly dosing chemically possible.

That is the real innovation here — not deeper weight loss, but a longer dosing interval. For someone who dislikes weekly injections or struggles to stay consistent, that could matter.

The Trial Numbers — and the Asterisk

In its Phase 2 trial (592 adults, 52 weeks), MariTide produced average weight loss in the range of 12.3% to 16.2% in participants without diabetes, on the intention-to-treat analysis (Jastreboff AM et al, New England Journal of Medicine, 2025). Notably, weight had not plateaued at 52 weeks — it was still trending down, which suggests longer treatment could yield more.

Here is the asterisk, and it is an honest one. “Once monthly” is not quite once monthly at the start. To make the drug tolerable, the Phase 3 program uses a three-step dose escalation — 21 mg, then 35 mg, then 70 mg over the first eight weeks — before reaching true monthly maintenance. Without that careful ramp-up, vomiting rates in Phase 2 were very high. With it, they dropped substantially. In other words, the convenience is real, but it arrives after a deliberate, supervised build-up — not from day one.

There is one early signal worth watching: in Phase 2, fat was reduced with lean tissue described as preserved — though this was not quantified as a headline number, so I will not overstate it. If it holds up in Phase 3, muscle preservation would be a meaningful advantage. We will know more when the larger trials report.

The Deeper Lesson for Chattanooga Patients

Here is what the MariTide story really teaches, and it is the thing I most want my patients to internalize: the hard part of weight-loss medicine is not how often you inject. It is everything that happens between the injections.

A longer dosing interval does nothing to solve the problems that actually determine your outcome — protecting muscle as you lose fat, managing side effects so you can stay on treatment, adjusting the dose to your body, and planning for what happens when you reach your goal. Those require a physician’s attention, not a different syringe schedule. A monthly shot from a faceless service is still a faceless service.

When MariTide and the other long-acting agents are approved and proven, I will look hard at whether monthly dosing genuinely helps a given patient stay consistent and reach their goal. Convenience that improves adherence is worth something. But convenience is not the same as care, and I will never pretend it is.

The Bottom Line for Chattanooga

A once-monthly injection is a real and interesting development — and it is still years away, still in trials, and still no substitute for a physician who knows your case. If you want to lose weight now, with proven medication and a plan built around keeping it off, you do not need to wait for MariTide. You need a doctor who reads your chart.

Apply in about five minutes at summitmetabolichealth.com/apply. I personally review every application and reach out — no algorithms, no sales calls.